Net sales 640,914 million yen (up 26.7% YoY), Core operating profit 221,417 million yen (up 55.6%), Core quarterly profit 170,472 million yen (up 62.8%). Full-year forecast for 2027: net sales 2,220,000 million yen, core operating profit 620,000 million yen, core net income 460,000 million yen. Dividend forecast for the fiscal year ending March 2027 remains at 80 yen (flat year over year).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4503-20260805-01.pdf","jir_short_summary":"Net sales 640,914 million yen (up 26.7% YoY), Core operating profit 221,417 million yen (up 55.6%), Core quarterly profit 170,472 million yen (up 62.8%). Full-year forecast for 2027: net sales 2,220,000 million yen, core operating profit 620,000 million yen, core net income 460,000 million yen. Dividend forecast for the fiscal year ending March 2027 remains at 80 yen (flat year over year).","jir_summary":"### Performance overview\nThis quarter's net sales expanded, with significant contributions from key strategic products such as PADCEV, IZERVAY, VYLOY, VEOZAH, XOSPATA, and XTANDI. Net sales were 640,914 million yen, with core metrics on a subtotal basis also markedly improved. Core operating profit was 221,417 million yen, and core quarterly profit was 170,472 million yen, demonstrating growth that more than offset currency effects and SG&A increases.\n\n### Outlook and dividend\nThe full-year forecast remains unchanged: net sales 2,220,000 million yen, core operating profit 620,000 million yen, and core net income 460,000 million yen, with an expectation of stable growth. Dividend for the fiscal year ending March 2027 is expected to be 80 yen, including the year-end dividend, totaling 80 yen for the year.","jir_financial_highlights":"Net sales: 640,914 (YoY 26.7% increase)\nCore operating profit: 221,417 (YoY +55.6%)\nCore quarterly profit: 170,472 (YoY +62.8%)\nNet income attributable to owners of parent (quarter): 141,828 (YoY +107.3%)\nEnding cash and cash equivalents: 244,698 (Decrease from prior year-end by 36.9 billion yen)","jir_category":"","jir_hashtags":"#AstellasPharma, #financial_summary, #JapanEquities","jir_key_figures":"Net sales: 640,914 million yen\nCore operating profit: 221,417 million yen\nCore quarterly profit: 170,472 million yen","jir_meta_title":"[Astellas Pharma] FY2027 Q1 Financial Summary \u2014 Net Sales 640,914 million yen, Core Profit Substantial Increase","jir_meta_description":"Highlights from Astellas Pharma's FY2027 Q1 financial summary. Increases in net sales and core profit, full-year outlook, and dividend policy summarized for investment decision-making.","jir_og_title":"[Astellas Pharma] FY2027 Q1 Financial Summary \u2014 Net Sales are not 64 trillion yen nor 64.0914 billion but 640,914 million yen","jir_og_description":"Astellas Pharma's Q1 financial results. Key points on net sales growth, core profit, full-year guidance, and dividend policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-Q4\\\",\\\"2027-Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[505794,640914]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-Q4\\\",\\\"2027-Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[142269,221417]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"core_profit_margin\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Net Profit Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-Q4\\\",\\\"2027-Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Profit Margin\\\",\\\"data\\\":[28.1,34.0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"region_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Geographical Revenue Composition\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"United States\\\",\\\"Japan\\\",\\\"Established Markets\\\",\\\"China\\\",\\\"International Markets\\\"],\\\"datasets\\\":[{\\\"data\\\":[2888,796,1522,321,854]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"comparison_vs_prior_guidance\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Performance vs Guidance\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Net Sales\\\",\\\"Core Operating Profit\\\",\\\"Core Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast\\\",\\\"data\\\":[2220000,620000,460000]},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[ original? ]}]},\\\"options\\\":{}}\"}]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95479","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n